🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Anil gets it. IMHO to give a patient ICI when they are admitted is more likely to keep them admitted. Also, every academic cancer center could produce this type of data if they wanted to pubmed.ncbi.nlm.nih.gov/36185315/

Just in time for the holidays! 🥂🎄 "Pour Decisions, or ASH-olutely Fabulous? Reviewing 2024 ASH Lymphoma Updates" #lymsm Anthony Perissinotti Bernie Marini Tycel Phillips creators.spotify.com/pod/show/wolve…

Late to this party but we cite all the experts Zahra M, PharmD, MBA, BCOP, FHOPA James Davis, PharmD, BCOP Amir Ali, PharmD, BCOP Victoria Nachar Robert Mancini, PharmD, BCOP, FHOPA Jill Lykon, PharmD, BCOP Raj Chakraborty Hamza Namira Katelynn Granger, PharmD, BCOP Noopur Raje Joshua Richter, MD, FACP Luciano J Costa Practical insights into bispecific antibody therapy tandfonline.com/doi/full/10.10…

Hi PGY2 Heme Onc Pharmacy Residents - looking for inpatient hematology clin pharm job after graduation!? UM has a new position available just for you. It’s all about the 🙌🏼💚🧡 UMiami Health System Sylvester Comprehensive Cancer Center Apply here: careers.miami.edu/us/en/job/R100…

“In some cases they may be trading an ancient drug of Socialization for the novel intoxicants of isolation” I used to say the great Bill Simmons was my favorite writer when “his fingers worked”, now I say Derek Thompson. Also appreciate the shout out to Vinay Prasad MD MPH in this pod.

‼️Impact of Quadruplet Induction Therapy on Stem Cell Mobilization Yields in Newly Diagnosed Multiple Myeloma 🧵 1/- A single Center retrospective study aims to characterize the impact of induction regimens (D-RVd or D-KRd) vs (RVd or KRd) on achieving patient-specific stem cell

In lieu of a head-to-head trial comparing ide-cel and cilta-cel (which we will never get), check out our study in Journal of Clinical Oncology comparing these products in over 600 patients. congrats #DorisHansen Krina Patel Surbhi Sidana, MD Danai Dima CharlotteBWagner ascopubs.org/doi/10.1200/JC…

L. F. GO Already know this episode is going to be rated Explicit….

I am presenting, technically. I'll be discussing the future of HOPARX during my incoming president's address Friday afternoon! Don't miss it, you'll laugh, you'll cry, you may even learn something (I know I will)! Hope to see you there!

What is the best treatment for high-risk APL? Are GO-based regimens better than APML4-style? 🤔 Check out our FIRST major multi-center hematology PharmD pub and find out! 👀 #leusm #apl #HEROconsortium onlinelibrary.wiley.com/doi/10.1002/aj…

Check out are latest episode, with a star-studded cast! 🤩 "Dex and the Cytokine City: Managing CRS with Bispecifics" #leusm #lymsm #myeloma #TwitteRx @berninini James Davis, PharmD, BCOP Victoria Nachar Anthony Perissinotti Justine Preedit creators.spotify.com/pod/show/wolve…

And James Davis, PharmD, BCOP and I were the first in line - come join us for a great #MMsm talk about optimizing myeloma therapies as pharmacists and physicians! Cc HOPARX

It is an honor to present at the Emil J. Freireich Leukemia Hematology Grand Rounds MD Anderson Cancer Center this morning! Thanks so much for the kind invitation! UNC Lineberger

Thrilled to announce I’ve been named the new PGY1 Acute Care RPD for UC Davis Health!! #TwitteRx I know this is a dying platform but please feel free to DM me with any questions 🤍🤍